Please select a
Axxam is an innovative Partner Research Organization (iPRO) and a leading provider of integrated discovery services across life sciences industries including: pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages. We have consolidated expertise across a broad range of discovery disciplines and innovative technologies including: assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural) or those provided by our clients, compound management, hit identification and hit validation. Our performance-driven approach has been recognized by our clients as key to the success for their discovery programs. Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures.
BIOINDUSTRY PARK SILVANO FUMERO S.p.A.
Bioindustry Park “Silvano Fumero” is a scientific park, whose mission is to promote and develop research in Life Sciences sector hosting and supporting companies, start-ups and research institutions of the chemical, biotech, pharmaceutical, diagnostic, medtech and digital health fields. The Park offers a full range of solutions and support services for the creation and development of life sciences and healthcare companies through facilities, scientific and business support services. It is the managing company of bioPmed, the healthcare cluster of Piedmont that involves private and R&D organisations related to biotech and medtech sectors. BioPmed is an innovation cluster which gathers about 100 companies, research centres and academic institutions. The cluster works with the most dynamic clusters in the world, with the goal to develop innovative technological solutions to sustain the growth of local companies and of the whole regional system, making it more solid and more competitive on the international markets.
Specific Reagents for BAG3 have shown different applications in the diagnosis and treatment of human diseases that have at the base a dysregulation of cell death such as, for example, those cancer and cardiovascular diseases. Since the beginning of its activity BIOUNIVERSA based its partnership strategy on continuous research and selection of external actors (biotech, Big Pharma, clinical centers of excellence worldwide, other research teams) can bring new skills and / or assets in-house team.
The goal is to develop new applications of BAG3 Platform and expand the pipeline. To date BIOUNIVERSA It boasts a significant number of partnerships with different types of players in the Red Biotech.
DIATHEVA is an Italian biotechnology company focused on the development of novel biologic therapeutics in oncology and infectious diseases areas. The company also develops and commercializes molecular and Immunoenzymatic diagnostic kits. The main product lines are dedicated to diagnosis, control and prevention of animal and human microbial infections including COVID-19. Most of the products realized by DIATHEVA are unique on the market. DIATHEVA hold a GMP production facility authorized to produce and release biological APIs and provides contract research and cGMP manufacturing services of biologics with a special emphasis on new immunogens, enzymes and antibody fragments. Diatheva is interested in finding out-licensing or partnering opportunities in oncology and fungal infections for the further development of its biologic therapeutics. The company is also interested in in-licensing of new product (biologics) in the field of cancer and infectious diseases-
HASSISTO - E-Health Platforms
E-health monitoring modular platform in domestic environments, for prevention and early detection of chronic diseases
lightScience srl started in February 2020 as an Italian innovative start-up to bring to the market its disruptive method to test blood samples on the go, based on NIR spectrometry, DBS cards for sampling cloud computing, and machine learning based chemometric calibration models. The founding team, since 2016, started to work on this approach designing and building a prototype, and registering an international patent.
LO.LI. PHARMA INTERNATIONAL
Lo.Li. Pharma International is an Italian pharmaceutical company operating from 2012.The company’s focus is Women’s Health, while the therapeutic areas covered are Gynecology, Obstetrics,Fertility (male and female), Endocrinology and Urology.We believe in supplying our partners with specific training and useful marketing tools in order to developsolid projects and fruitful and cooperationOur products are currently marketed successfully in more than 60 countries worldwide. We are constantlylooking for distributors from all over the world who share our values and are willing to expand theirportfolio with our finished products in order to establish win-win partnerships
MENARINI SILICON BIOSYSTEMS
Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization. CELLSEARCH® is the first and only clinically validated blood test cleared by the FDA for detecting and counting Circulating Tumor Cells (CTCs) to aid in managing patients with metastatic breast, prostate, and colorectal cancers when used in conjunction with other clinical methods (for full intended use see documents.cellsearchctc.com) DEPArray™ (for Research Use Only) is an image-based digital cell-sorting and isolation platform that enables clinical researchers to study rare cells with single-cell precision. The integration of CELLSEARCH® and DEPArray™ technologies provide an end-to-end workflow solution* for the enumeration, sorting, and molecular characterization of rare cells with single cell precision. Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.
OLON is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO). Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in USA and 1 in India and 3 branch offices in Hamburg (Germany), Florham Park NJ (USA) and Shanghai (China). OLON Biotechnology Centres represent one of the most extensive know-how of microbial fermentation in Europe. Expertise and competence are combined with great flexibility at different levels related to the knowledge of various microorganisms and fermentation processes. Our flexibility also reflects in the isolation and purification steps because we can rely on 20 different downstream plants. We can offer to third parties our size and capacity of 4,500m3 for a wide range of proteins, enzymes, peptides, recombinant-technology products.
Plasfer srl is a pre-clinical stage biopharmaceutical company developing next-generation cell-based therapeutics using platelets and platelet-derived microparticles for drug-delivery and cell therapy applications. Platelet transfer technology (PTT TM ) is a proprietary technology platform able to load/engineer platelets at high efficiency with an array of different molecular entities without altering their natural morphology and functionality. Using PTT TM Plasfer is currently developing two clinical candidates: PLA-GBM and PLA-ONCO. PLA-GBM is a clinical product consisting of a PTT-platelet concentrate aiming at delivering RNAi (siRNA-miRNA) for the treatment of Glioblastoma R/R (IDH-wildtype IV grade glioma) after surgical removal. PLA-ONCO is a clinical product consisting of a PTT-platelet concentrate that aims at delivering siRNA for the treatment of Solid Tumors, i.e., Pancreatic, Ovarian and Melanoma.
Since 1997, Promete focuses its business on R&D and on bringing to the market new ideas from research to approach new business opportunities in selected niche markets. The company considers as main growth drivers the investment in IP, in the expertise in frontier applications and in high value-added and innovative products/services jointly developed through partnerships and collaborative actions with public and private entities. Promete will present some of its products in Bio Japan 2021, which are Trylight, Ramona and MIDA. Briefly, TRYLIGHT works for Surface functionalization which is a key step in biosensing since it is the basis of an effective analyte recognition; RaMonA is an instrument for the detection of radon gas accumulation level, designed for safe and comfortable use; and MIDA is a magnetoelastic biosensor for the rapid and economic detection of food pathogens.
ReiThera is a biotech company dedicated to the development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies. The company has a long-standing expertise in the development of scalable processes for viral vector manufacturing, supported by a cGMP facility inclusive of filling suite and quality control laboratories. ReIthera operates as CDMO offering process development and GMP production of viral vectors based on AV, AAV, MVA, etc and can also offer proprietary cell substrates for viral productions. In this context, ReiThara bases its core capacity in a state-of-the-art facility including stirred-tank bioreactors supporting a working volume at the scale of 200L, 1000L and 2000L for production in suspension and fixed bed bioreactors with a surface up to 30 m 2 for adherent growth of the cell substrate. ReiThera is welcome to meet company interested in exploring the possibility of performing process development and GMP production at ReiThera.
Remembrane designs, develops and manufactures customised GMP-grade membrane-targeting Lipid Mixtures commercialized under the brand name Refeed. Refeed are a revolutionary family of membrane-targeting Lipid Mixtures suitable for any type of cultured cells and protocol used in biolaboratories and able to make any cell culture processes more efficient and cost-effective. Refeed are able to modify the membrane lipid content of cultured cells, developing different membrane phenotypes and modifying selected cell properties in any kind of cultured cells, from microorganisms (E. coli, yeast, etc.) to human cells (cell lines, primary cells, stem cells). Refeed improve valuable biological parameters of cultured cells such as the yields of BIOMANUFACTURING processes (Proteins, Viruses and Viral Vectors, Chemicals, Bioplastics, etc), the efficacy and outcome of ADVANCED THERAPIES, the quality of drug efficacy and toxicity IN-VITRO TESTING. Refeed are used by a widespread plethora of many international customers of the pharmaceutical and industrial biotechnology sectors.
Our mission is to improve the well-being of people. We do with Intelligent Nebulizers and with Functional Fragrances for the stimulation of brain plasticity. Our start-up was born in 2020 during the pandemic in Rome and at the Innovation Hub – Polo Meccatornica of Rovereto. It is composed of an entrepreneurial and research team with experience and actively collaborates with Fondazione Bruno Kessler, University of Trento, Catholic University of the Sacred Heart and Luiss University for research and development activities. We started now with S 1* , the only patented technology in the world that allow to automate and certify the process of sanitizing of spaces and surfaces today carried out by qualified personnel from cleaning and facility companies.
S 1* covers a space of 100sqm that can be implemented by adding additional S 1 for every 100sqm ensuring the certification of sanitization spaces and surfaces.
For almost a century and a half, Studio Torta has played a key role in protecting some of the most relevant patents, high profile brands and innovative designs worldwide. Our focus has always been on clients, collaborating and innovating with them to create bespoke solutions that protect and help their businesses grow. The long-standing legal experience of our senior partners is complemented by the expertise of talented junior partners on emerging technologies, with a view to meeting the needs of a constantly evolving market. Studio Torta operates as a joint-stock company with 59 practitioners, 39 of whom are partners plus 131 staff members. It has offices in Turin, Milan, Treviso, Bologna, Rimini and Rome and can count on a consolidated network of
correspondents worldwide. Moreover, to ensure excellent assistance to clients abroad, amongst out staff we have Chinese, Japanese, German and French native speakers.
Vera Salus Ricerca (VSR) is a well-established technology discovery company, specialized in biomedical research applied to the development of innovative products in the drug and food industry. VSR has recently launched the Dream Factory Project, which exploits company unique operations to implement a new business model based on innovation transfer, transversally to other biotech companies. The core of this Project is represented by VSR’s proprietary compound platforms Flav-X, semi-synthetic small molecules derived from Flavonoids, and Natur-X, a natural compound collection from plants and fruits. Flav-X and Natur-X are unlimited chemical libraries conceived to support the innovative design of drugs or food ingredients for novel, powerful technologies. Leveraging on its innovative operating model and international, multidisciplinary expertise, VSR generates specific, tailor-made innovation and confers diversification and profit-gains to client companies. Potential stakeholders interested in working with VSR include private investors, biotechs from food and nutraceutical sectors and pharma companies.